Patient Care
Our Commitment
Patient Partnership
We have always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest, we want to give all people the opportunity to be the best version of themselves by having access to affordable, innovative and sustainable healthcare.
In 2025, we established a Patient Partnership function at the Group level, marking a pivotal step in our transformation journey. This initiative reflects our commitment to change management—not only in how we work for patients, but in how we actively and intentionally collaborate with them. We then committed to embark on a journey to shape a culture where patients are genuinely recognised as partners in care.
Systematic Patient Engagement
At Recordati, Patient partnership represents a powerful opportunity to co-create therapies and innovations that truly address outcomes that matter. Our integrated strategy aims to help us move beyond ad hoc involvement to systematic engagement across the entire drug development lifecycle and patient journey. By embedding lived experiences into trial design, regulatory dialogue, and strategic decision-making, we strive to ensure that outcomes most important to patients are reflected in every stage of medicines development and beyond.
How we facilitate access to medicine and healthcare
FOCUSED ON THE FEW
We care for the most vulnerable patients through our dedicated business unit Recordati Rare Diseases and through specific Patient Access Programmes.
In the context of facilitating access to treatments, in 2025 Recordati Rare Diseases continued to support two programmes to provide assistance to patients eligible to receive support for the costs related to its products: the Patient Assistance Program (PAP) and the Co-Pay Assistance Program (CAP).*
During 2025, Recordati supported around 1,450 rare disease patients with the Patient Assistance Program (PAP), Co-Pay Assistance Program (CAP) and similar programmes.
*In 2025, these two programmes were active in the USA
and China, and focused on the endocrinology, oncology
and metabolic therapeutic areas.
INNOVATIVE MEDICINE
We are focused on developing and offering innovative products, in areas where we can make a difference, and with the aim of improving human health and quality of life. To this end, we invest in research and development including life cycle management (in rare diseases), as well as maintaining the highest product quality and safety standards throughout the product life cycle. The central importance of patients, including the most vulnerable is an integrated part of our strategy.
SUPPORTING PATIENT ASSOCIATIONS, CAREGIVERS, DOCTORS AND INSTITUTIONS
Our goal is to increase awareness, promote improved diagnosis, and expand the availability of treatments, especially for people with rare diseases.
ACCESS TO QUALITY CARE
Through the Specialty & Primary Care division, we continue to provide high-quality and affordable products for a broad range of therapeutic areas, including low- and middle-income countries.
PRODUCT DONATIONS
Through donations of medicinal products to disadvantaged people who are unable to purchase medicines, or during times of humanitarian emergency.*
*In 2025, total product donations amounted to approximately 940,000 euros (250,000 euros in 2024). Product donations are measured at market
value. The amount of product donations is included in the total sum of donations shown in chapter “Support for local communities”.
Patient Care
Our Approach Towards Patients
“In 2025, we made meaningful progress across our R&D pipeline, bringing in new innovation from the outside, as well as advancing new indications and geographic expansion for our existing portfolio. Our targeted R&D investments focus on addressing unmet medical needs in rare diseases while maximising the value of our broader portfolio through effective lifecycle management, ultimately aiming to improve outcomes for patients.”
Milan Zdravkovic
Executive Vice President, R&D and Chief Medical Officer
Patient Care
Empowering Lives
Specialty & Primary Care: Improving Patient Care & Education
Recordati has a strong and proven heritage of supporting people living with a wide range of common illnesses that affect large populations every day – creating value for patients, payers and physicians across specialty and primary care with both prescription and self-medication treatments.
In 2025, Recordati launched several initiatives to improve patient care and education on prescription and OTC medicines.
Some examples are given below:
Initiatives by the SPC Division
Health Caravans Project in Tunisia
In 2025 the “Health Caravans” project continued in Tunisia, aiming to provide access to specialist medical treatment in the most underserved rural areas of the country. The initiative involved a team of specialist doctors, including cardiologists and pulmonologists, with over 1,000 patient visits conducted. Access to healthcare remains a challenge in Tunisia, especially in rural areas.
The health caravans are a further iteration our commitment to reduce health inequality and provide equal access to treatments, with the goal of promoting wellbeing and improving quality of life for vulnerable communities. Based on the success of previous editions of the project, in 2026 the initiative will be rolled out to new areas of Tunisia in order to raise awareness on prevention and early diagnosis among an increasingly wider audience.
Go Beyond
A prostate cancer diagnosis can leave many men unsure of what lies ahead and feeling disconnected from their sense of self. The journey beyond diagnosis often raises new questions – how to adapt and how to continue living life to the full after the disease?
GO BEYOND embodies our ongoing commitment to support men through this transition, offering clear guidance, practical tools and reassurance to help them get back their confidence and purpose. Over the past year, the programme has continued to develop, with materials now available in several countries and through international partners, adapted into a variety of practical resources containing exercise, nutrition and lifestyle advice for men with prostate cancer.
Breaking the Taboo:#IHadItToo
With #IHadItToo, we are committed to empowering young women with the knowledge and support they need to understand vaginal infections, recognise symptoms early and make informed treatment choices – while promoting overall well-being. In 2025, we continued targeted initiatives to elevate education, normalise conversation and encourage confident, responsible self-care. #IHadItToo embodies our ongoing commitment to breaking the taboo and offering clear, practical guidance. The programme provides accessible explanations of common causes, easy-to-follow symptom checklists and evidence-based treatment pathways – all designed to help young women feel informed and supported.
Patient Care
Focused on the Few
Rare Diseases: Our Commitment to the Patient Community
We focus on the few, those affected by rare diseases, and we believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions. For us, patient centricity represents a partnership with the patient community, ensuring that their voices are integral to creating effective, patient-aligned healthcare solutions.
Raising Awareness of Rare Diseases: Main Initiatives
Inauguration of the Flagship Global Educational Programme aCADemy
In 2025, medical education was a big focus for cold agglutinin disease (CAD), with the inauguration of the flagship global educational programme aCADemy focused on raising CAD awareness and expertise and sharing best practice amongst HCPs from across the globe. We also participated in the sponsorship of the world’s biggest haematology congress, the annual meeting of the Americal Society of Haematology (ASH), with an independent CME accredited educational symposium focused on three rare haematological diseases, CAD, iMCD and acute porphyria, offering HCPs the opportunity to enhance their knowledge for treating patients with these conditions.
Strengthening Engagement with the Global iMCD Community
We continued in 2025 our close collaboration with the Castleman Disease Collaborative Network (CDCN), supporting both the Patient & Loved One Summit and the Physician & Researcher Annual Meeting at ASH, two cornerstone events that foster education, connection, and scientific exchange. In addition, we hosted two Global Patient Forums in partnership with international patient communities, creating space for dialogue, shared learning, and capacity building across the world. A key highlight of the year was the iMCD in Focus Masterclass in Barcelona, which brought together over 85 healthcare professionals from around the world. The meeting provided an interactive forum to discuss the latest evidence, share real-world experience, and align on best practices in iMCD management.
“ECO” Project: Giving a Voice to Patient Associations
In 2025, with the goal of creating a space to be heard and talk about experiences and real needs, exchange best practices and build concrete projects together, the ECO Project was created in Italy. Created with and for patients, the initiative brought together the rare disease associations and non-profit foundations with whom Recordati Rare Diseases collaborates. The objective of this meeting was to give the opportunity to these patient representatives to share their experiences and spread their patient voice, including some challenges that the patient community is facing in the country, as well as some success stories and needs for the future
Recordati Rare Diseases Fondation d’Entreprise
The Recordati Rare Diseases Foundation was established to independently support training programmes for the scientific community, guided by an external scientific committee.
In 2025, the Foundation continued to demonstrate its dedication to advancing medical education and improving patient outcomes: it organised three in person, high-impact, accredited courses which addressed critical topics in rare disease diagnosis and management. The first one focused on liver and liver-kidney transplantation for inherited metabolic disorders, the second on leukodystrophies, and the third on neuroendocrine tumour syndromes.
Q-Bags for Children Undergoing Treatment for High-risk Neuroblastoma
The Q-Bag Project, developed specifically for children undergoing therapy for high-risk neuroblastoma, was launched in 2024. Neuroblastoma is a rare and aggressive cancer that mainly affects young children. Treatment often requires intravenous (IV) infusions for several months. During this period, children must carry around bulky IV equipment, such as pumps and pill boxes, which greatly limit their mobility and, as a result, their ability to play, move freely and simply be children. To address this challenge, Recordati Rare Diseases collaborated with the hospital Princess Máxima Center for Pediatric Oncology in the Netherlands and with a specialist design agency to create the Q-Bag: a childfriendly backpack designed to safely hold the IV pumps. The Q-Bag protects the medical equipment and offers children greater freedom and independence during therapy.
In 2025, the project moved on to the next phase: making the Q-Bag compatible with all pump types. Innovative technologies will make it possible to develop a universal model that can be used across the world, thereby increasing the number of patients and caregivers who can benefit from this solution.
Discover More about Our Commitment to Patients
For more information, please refer to the Consolidated Sustainability Statement.